Data præsenteret fra kontrollerede studier inkluderede 1357 patienter, hvoraf 766 modtog Aranesp og 591 patienter modtog r- HuEPO.
Data presented from controlled studies included 1357 patients, 766 who received Aranesp and 591 patients who received r-HuEPO.